A Role for Collapsin-1 in Olfactory and Cranial Sensory Axon Guidance

Hiroaki Kobayashi, Adam M. Koppel, Yuling Luo, and Jonathan A. Raper

Department of Neuroscience, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104

Collapsin-1 is a member of the semaphorin family of signaling molecules that acts as a repellent for growing spinal sensory axons. We have constructed a chimeric collapsin-1/alkaline phosphatase probe to visualize putative collapsin-1 receptors in vitro and in situ. As predicted by the activity profile of collapsin-1, the probe binds spinal sensory tracts, ventral spinal roots, and the sympathetic chain but does not bind retinal axons. In addition, we find that the probe binds sensory axons arising from the olfactory epithelium and some, but not all, cranial sensory nerves. As predicted by these binding studies, in vitro assays demonstrate that primary olfactory sensory, trigeminal, and jugular ganglion growth cones collapse in the presence of soluble collapsin-1. Comparing the expression pattern of collapsin-1 with the trajectories of collapsin-1-responsive axons suggests that in both the spinal cord and the olfactory bulb, collapsin-1 prevents premature entry of sensory axons into their target and helps determine the final location of sensory terminations.

Key words: collapsin-1; semaphorin-III; semaphorin-D; olfactory bulb; chick hindbrain; axon guidance; alkaline phosphatase fusion protein; collapsin-1 receptors

Received May 23, 1997; revised Aug. 11, 1997; accepted Aug. 13, 1997.

This work was supported by grants from the National Institutes of Health and the McKnight Foundation. Hiroaki Kobayashi is supported by a fellowship from the Japanese Society for the Promotion of Science. We thank Dr. John Flanagan for plasmids to generate AP fusion protein and Dr. Steven Scherer for his kind advice on preparing frozen sections.

Correspondence should be addressed to Dr. Hiroaki Kobayashi, 105 Johnson Pavilion, Department of Neuroscience, University of Pennsylvania School of Medicine, 3600 Hamilton Walk, Philadelphia, PA 19104.

Copyright © 1997 Society for Neuroscience 0270-6474/97/178339-14$05.00/0
Materials. The following materials were obtained from the indicated sources: nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophin-4 (NT4) from Alamine Labs (Jerusalem, Israel); progesterone, nitroblue tetrazolium (NBT), and 5-bromo-4-chloro-3-indolyl phosphate (BCIP) from Sigma (St. Louis, MO); insulin, transferrin, and putrescine from Collaborative Research (Bedford, MA); fetal calf serum (FCS) and laminin from Life Technologies (Grand Island, NY); nitrocellulose paper from Schleicher & Schuell (Keene, NH); slot blot apparatus, Hoefer PR-648, from Hoefer Pharmacia Biotech (San Francisco, CA); EX CELL 405 from JRH Biosciences (Lenexa, KS); 1,`-dioctadecyl-3,3,3`,3`-tetramethylindocarbocyanine perchlorate (DiI) from Molecular Probes (Eugene, OR); Dispase II and alkaline phosphatase-conjugated anti-digoxigenin (DIG) antibodies from Boehringer Mannheim (Mannheim, Germany); Cy3-conjugated antibody from Jackson ImmunoResearch (West Grove, PA); Tissue-Tek OCT compound from Sakura (Tokyo, Japan); and superfrost slides from Fisher Scientific (Pittsburgh, PA).

Construction and expression of alkaline phosphatase fusion proteins. Plasmids containing alkaline phosphatase (AP) were the generous gift of Dr. John Flanagan. One contained AP with a stop codon (C-terminal fusion); the other contained AP with a leading signal sequence (N-terminal fusion). To produce Col-1–AP, we cut out the AP sequence from the vector and inserted this sequence after the C-terminal end of the coding sequence for collapsin-1. The amino acid sequence at the junction between collapsin-1 and AP was PRSV-(LE)-IIPV, with PRSV in collapsin-1. The two amino acids in parenthesis served as a linker. To produce AP–Col-1, we replaced the signal sequence of collapsin-1 with the AP signal and coding sequences. The amino acid sequence at the junction between AP and collapsin-1 was SGRS-(GS)-KNNV, with KNNV in collapsin-1. Recombinant protein was produced using the expression plasmid pAG3, derived from a pcDNA3 backbone (Invitrogen, San Diego, CA) with a cytomegalovirus enhancer, a chick beta-globin splice site, a bovine growth hormone polyadenylation site, and a hygromycin resistance gene (Miyazaki et al., 1989). These two constructs, Col-1–AP and AP–Col-1, were transfected into transformed human kidney epithelial cells (293T) using calcium phosphate precipitation. Chloroquine (1:1000 of 25 mM stock solution) was added to the cells at the time of transfection. After a 4–5 hr incubation at 37°C, the cells were washed and cultured in DMEM with 10% heat-inactivated FBS. Conditioned media containing the secreted fusion proteins were collected 20 hr later.

Determining AP-collapsin-1 concentrations. To determine the relative amounts of AP-collapsin-1 fusion proteins produced in each transfection, we blotted a dilution series of culture supernatants onto nitrocellulose paper with a Hoefer slot blot apparatus and reacted the series for AP activity. Supernatants were diluted with DMEM containing 10% heat-inactivated FBS. The nitrocellulose paper was rinsed in PBS and heat-inactivated at 65°C for 3 hr in PBS. The paper was then reacted with an AP reaction mixture containing 100 mM Tris, pH 9.5, 100 mM NaCl, 5 mM MgCl2, 0.33 mg/ml NBT, and 0.17 mg/ml BCIP. To compare the relative amounts of AP-collapsin-1 and standardized unlabeled collapsin-1 of known potency, we probed slot blots with monoclonal collapsin-1 binding by mAb E7 (see Materials and Methods). C, Equilibrium binding of AP–Col-1 to dissociated sympathetic neurons. Sympathetic neurons were incubated with various concentrations of AP–Col-1 at 37°C for 1 hr. The cells were then fixed, washed, and assayed colorimetrically for bound AP activity. The AP–Col-1 binding to sympathetic neurons is saturable, and the Kd is estimated as 800 pM. Inset, Scatchard plot from the same data. The data are well fitted with a straight line. D, Binding kinetics of AP–Col-1 to dissociated sympathetic neurons at lower concentrations of the ligand. Data points are fitted with either a two or one binding-site model by nonlinear regression analysis. Data points are better fitted with the two (solid line) than with the one (dashed line) binding-site model. The Kd for the high affinity sites is 30 ps. Inset, Scatchard plot from the same data showing the presence of two binding sites. Similar results were seen in six of seven independent experiments.

Figure 1. Characteristics of alkaline phosphatase-fused collapsin-1. A, A schematic diagram of the probes used in this study. Collapsin-1 (brackets) consists of its own signal sequence (SS), a semaphorin domain (SEMA), a C2-type immunoglobulin domain (Ig), and a positively charged C-terminal tail (+ +). a, The Col-1–AP probe has alkaline phosphatase (AP) fused just after the basic tail of collapsin-1. b, The AP–Col-1 probe has a signal sequence and AP fused onto the N-terminal end of collapsin-1. B, The relative responsiveness of chick E7 DRG growth cones to medium conditioned by 293T cells transfected with collapsin-1 (closed circles), AP–Col-1 (open circles), and Col-1–AP (open squares). The percentages of collapsed growth cones are plotted against the log of the estimated concentrations of collapsin-1 or AP-fused collapsin-1. The concentrations of collapsin-1 and AP-fused collapsin-1 in the medium were estimated by comparing the AP activities and/or the amount of
antibody (mAb) E7 anti-collapsin-1 and detected them with a HRP-conjugated secondary antibody (Jackson ImmunoResearch, West Grove, PA). Estimates of relative collapsin-1 and AP–collapsin-1 concentrations were accurate to approximately a factor of two when the relative intensities of the dilution series were matched by eye.

Col-1–AP binding to cultures. DRGs from E7 chick embryos or retinae from E6 embryos were cultured in 0.5 ml of medium on glass coverslips coated with laminin as described under Cell culture. One to 10 μl of 293T cell culture supernatant containing Col-1–AP were then added to each explant culture and incubated for 1 hr at 37°C. The culture was fixed by the addition of 4% paraformaldehyde, 10% sucrose, and PBS. After 30 min, the culture was washed with PBS several times, the endogenous alkaline phosphatase was heat-inactivated at 65°C for 2 hr, and the culture was processed for AP reaction. For experiments in which unlabeled collapsin-1 was used to compete with Col-1–AP binding, 10 μl of Col-1–AP containing supernatant was mixed with 10 μl (containing a 20–200-fold greater concentration) of unlabeled collapsin-1 produced in a baculovirus high-expression system. The mixture was added to explant cultures and processed as described above.

Quantitative estimation of AP-Col-1 binding to cultured sympathetic cells. Approximately 5 × 10^4 dissociated sympathetic neurons were plated into each well in a 48 well plate and cultured overnight. Then AP-Col-1 was added to each well at a series of protein concentrations ranging from 8 pM to 0.4 nM, and the cultures were incubated at 37°C for 1 hr. The cultures were then fixed in 4% paraformaldehyde for 30 min, washed three times with a buffer of 0.15 M NaCl and 20 mM HEPES, pH 7.4, and incubated at 65°C for 2.5 hr to destroy the endogenous alkaline phosphatase activity. The AP–Col-1 binding activity was determined colorimetrically by measuring optical density 415 after incubation in 200 μl of 1 M diethanolamine, pH 9.8, 0.5 mM MgCl₂, 10 mM L-homoarginine, 0.5 mg/ml BSA, and 12 mM p-nitrophenyl phosphate for 6–10 hr. Nonspecific binding was determined through the addition of a 100-fold excess of recombinant collapsin-1 with AP-Col-1 and was found to be <5% of the total binding activity. The binding data were analyzed either by the Prism II ligand analysis program or by Sigma plot.

Col-1–AP binding to sections. Chick embryos were decapitated, embedded in Tissue-Tek OCT compound, and frozen in a dry ice–acetone bath. Frozen sections were cut with a cryostat and collected on Superfrost Plus slides. Care was taken not to allow the sections to dry out. After being picked up, they were allowed to attach to the slides in a moist chamber for 2–3 min. They were then immediately frozen by putting the slides onto a precooled metal stage in the cryostat. Sections were postfixed within 1 hr of being cut with precooled methanol at −20°C for 7–10 min. They were then washed with PBS for 5 min twice and blocked with PBS containing 10% FBS for 15 min at 20°C. Sections were incubated with diluted 293T cell culture supernatants containing Col-1–AP at 20°C for 1 hr. Depending on the efficiency of transfection, 293T cell culture supernatants contained 2000–5000 collapsing units (CU)/ml, and dilutions between 1:20 and 1:100 were used. Sections were rinsed with PBS; fixed with 60% acetone, 3% paraformaldehyde, and 20 mM HEPES, pH 7.0, for 3 min; and then washed with PBS several times. Sections were then incubated at 65°C for 3 hr to inactivate endogenous alkaline phosphatases. Sections were then processed for AP in 100 mM Tris, pH 9.5, 100 mM NaCl, 5 mM MgCl₂, 0.33 mg/ml NBT, and 0.17 mg/ml BCIP at 20°C overnight. For experiments in which unlabeled collapsin-1 competed with Col-1–AP binding, collapsin-1 obtained from either a baculovirus expression system or 293T cells was used. Sections were prepared in the same way as described above and first preincubated with unlabeled collapsin-1 for 15 min and then incubated with the mixture of the probe and unlabeled collapsin-1 for 1 hr and processed the same way.

Figure 2. Col-1–AP labels DRGs but not retinal axons in vitro. Explanted E7 DRGs or fragments of E6 retina were incubated with Col-1–AP, fixed, and stained for bound AP activity. A, DRG axons in the absence of probe do not generate an AP reaction product. B, DRG axons exposed to 50 CU of Col-1–AP stain strongly. C, A control DRG growth cone has no endogenous AP activity. D, A DRG growth cone exposed to 50 CU of Col-1–AP is collapsed and strongly stained to its tip. E, DRG axons simultaneously exposed to 50 CU of Col-1–AP and a 200-fold excess of unlabeled collapsin-1 do not stain. F, Retinal axons treated with 50 CU of Col-1–AP do not stain. Scale bar, 20 μm.
Figure 3. AP–Col-1 labels central and peripheral DRG projections in sections. A, The dorsal sensory columns (DC, arrowhead) within the spinal cord are intensely labeled by 20 CU of AP–Col-1 in transverse sections of a stage 26 embryo spinal cord. B, A section from the same embryo simultaneously exposed to AP–Col-1 and an ~200-fold excess of unlabeled collapsin-1 is unstained. C, The peripheral nerve (PN) and the sympathetic chain (SC) are intensely labeled by AP–Col-1 in a section through the leg of a stage 27 embryo. drg, Dorsal root ganglion. D, the ventral root (VR) is stained with AP–Col-1 in a section through a stage 21 spinal cord. Scale bar, 200 μm.
Figure 4. Two classes of sensory afferents are differentially labeled in the developing spinal cord. A, AP–Col-1 binds to dorsal column sensory tracts in a transverse section of stage 30 lumbar spinal cord. B, An in situ hybridization for collapsin-1 mRNA demonstrates its medial and ventral distribution in a stage 30 spinal cord. C, AP–Col-1 binds to the dorsal columns and dorsally terminating sensory afferents of a stage 38 spinal cord. There is no detectable labeling of ventrally terminating sensory afferents. D, An in situ hybridization for collapsin-1 mRNA demonstrates its ventral distribution in a stage 38 spinal cord. Different specimens were used for AP–Col-1 staining and for in situ hybridizations because the two techniques are incompatible. Scale bar, 200 μm.
Figure 5. AP–Col-1 labeling in the cranial sensory tracts in the hindbrain. A, AP–Col-1 labels axons exiting the Vth (trigeminal) ganglion in a transverse section of stage 25 embryo hindbrain. The ophthalmic (oph) and maxillary nerves (mx) are labeled in the periphery, and the descending trigeminal tract (SpT) is labeled within the hindbrain (HB). B, The same section probed with an antibody to neurofilament shows the location of other axonal tracts unlabeled with AP–Col-1. The neurofilament staining is masked by the AP reaction product where AP–Col-1 is bound. Eye; V, trigeminal ganglion. C, An in situ hybridization for collapsin-1 mRNA at the entry point for the Vth nerve (V) into the hindbrain (Figure legend continues).
When double-stained for neurofilament and AP-Col-1, sections were prepared in the same way but were first blocked with PBS containing 10% FBS and then were incubated with a mixture of hybridoma culture supernatant (4H6, anti-neurofilament) and AP–Col-1. The sections were then fixed, washed, heat-inactivated, and incubated with Cy3-conjugated secondary antibody for 2 hr. Sections were then fixed again, washed with PBS, and processed for AP.

Reconstruction. Images of tissue sections were taken through a telecine camera (Hamamatsu; C2400) attached to an inverted Zeiss microscope. Images were then projected onto a television monitor screen (Sony, Tokyo, Japan; PVM-122) and traced onto transparent sheets. These tracings were scanned into Adobe Photoshop. Schematics were based on reconstructions generated by this method.

In situ hybridization. In situ hybridizations were performed as described previously with only minor variations (Shepherd et al., 1996). Sections were cut at 30 µm, and prehybridizations were performed for 1 hr at 65°C. Alkaline phosphatase-conjugated anti-DIG antibodies were used at a 1:2500 dilution. The AP reaction was performed as described under Col-1–AP binding to sections.

Cell culture. DRGs were dissected from E6 or E7 chick embryos and retinas from E6 embryos. Explants were plated onto 10 mm coverslips coated previously with 16 µg/ml laminin for 24 hr in the presence of 16 µM NaHCO₃ and 100 ng/ml streptomycin, 6 mg/ml glucose, 5 mM glutamine, 2 mM MOPS, and prehybridizations were performed for 1 hr at 37°C. Alkaline phosphatase-conjugated anti-DIG antibodies were used at a 1:2500 dilution. The AP reaction was performed as described under Col-1–AP binding to sections.

Cell culture. DRGs were dissected from E6 or E7 chick embryos and retinas from E6 embryos. Explants were plated onto 10 mm coverslips coated previously with 16 µg/ml laminin for 24 hr in the presence of 16 µM NaHCO₃ and 100 ng/ml streptomycin, 6 mg/ml glucose, 5 mM glutamine, 2 mM MOPS, and prehybridizations were performed for 1 hr at 37°C. Alkaline phosphatase-conjugated anti-DIG antibodies were used at a 1:2500 dilution. The AP reaction was performed as described under Col-1–AP binding to sections.

Results

Collapsin-1 alkaline phosphatase fusion construct

Recombinant fusion proteins consisting of human placental alkaline phosphatase and the full coding sequence of collapsin-1 were produced in transiently transfected human 293T cells. Two different chimeras were made (Fig. 1A), one with alkaline phosphatase fused to the C-terminal end of collapsin-1 and another with the enzyme fused to the N-terminal end (Col-1–AP) and another with the enzyme fused to the N-terminal end (Col-1–AP). To verify that collapsin-1 function is not compromised by the addition of alkaline phosphatase, we tested these fusion proteins for sensory growth cone collapsing activity in an in vitro assay. The specific collapsing activities of both the AP–Col-1 and Col-1–AP fusion proteins are as high or higher than that of collapsin-1 itself (Fig. 1B).

Visualization of collapsin-1 binding on cultured explants

Collapsin-1 is known to induce the collapse of DRG but not of retinal growth cones in vitro (Luo et al., 1993). A plausible inference is that DRG growth cones will bind collapsin-1, whereas retinal axons may not. Axons extending from E7 DRG explants were incubated with Col-1–AP for 1 hr at 37°C and fixed. The presence of alkaline phosphatase reaction product demonstrates the binding of collapsin-1 to DRG axons (Fig. 2B). Not only axons, but also collapsed growth cones, are intensely labeled with Col-1–AP (Fig. 2D). No binding is observed in the explants themselves or in migrating non-neuronal cells. We compared the collapsing activity and intensity of the AP signal at various concentrations of the Col-1–AP probe. If a CU is defined as the concentration of collapsin-1 required to collapse 50% of DRG growth cones, the binding of Col-1–AP to DRG axons is first detected at 5 CU, although staining intensity at this concentration is weak (data not shown). Fifty collapsing units, or ~100 ng/ml, give a strong AP signal. To test the specificity of the Col-1–AP signal, we tested whether unlabeled collapsin-1 could compete with Col-1–AP binding. No Col-1–AP binding is detected in DRG cultures simultaneously exposed to a 20-fold excess (~20 µg/ml) of unlabeled collapsin-1 (Fig. 2E). Even a 20-fold excess of unlabeled collapsin-1 reduces the intensity of the staining significantly (data not shown). The specificity of Col-1–AP binding was confirmed further by testing its ability to bind retinal growth cones. No detectable AP reaction product is observed on retinal ganglion cell axons or growth cones incubated in concentrations of Col-1–AP that give strong DRG labeling (Fig.

---

Kobayashi et al. / Sensory Axons Bind and Respond to Collapsin-1


---

When double-stained for neurofilament and AP-Col-1, sections were prepared in the same way but were first blocked with PBS containing 10% FBS and then were incubated with a mixture of hybridoma culture supernatant (4H6, anti-neurofilament) and AP–Col-1. The sections were then fixed, washed, heat-inactivated, and incubated with Cy3-conjugated secondary antibody for 2 hr. Sections were then fixed again, washed with PBS, and processed for AP.

Reconstruction. Images of tissue sections were taken through a telecine camera (Hamamatsu; C2400) attached to an inverted Zeiss microscope. Images were then projected onto a television monitor screen (Sony, Tokyo, Japan; PVM-122) and traced onto transparent sheets. These tracings were scanned into Adobe Photoshop. Schematics were based on reconstructions generated by this method.

In situ hybridization. In situ hybridizations were performed as described previously with only minor variations (Shepherd et al., 1996). Sections were cut at 30 µm, and prehybridizations were performed for 1 hr at 65°C. Alkaline phosphatase-conjugated anti-DIG antibodies were used at a 1:2500 dilution. The AP reaction was performed as described under Col-1–AP binding to sections.

Cell culture. DRGs were dissected from E6 or E7 chick embryos and retinas from E6 embryos. Explants were plated onto 10 mm coverslips coated previously with 16 µg/ml laminin for 24 hr in the presence of 16 µM NaHCO₃ and 100 ng/ml streptomycin, 6 mg/ml glucose, 5 mM glutamine, 2 mM MOPS, and prehybridizations were performed for 1 hr at 37°C. Alkaline phosphatase-conjugated anti-DIG antibodies were used at a 1:2500 dilution. The AP reaction was performed as described under Col-1–AP binding to sections.

Results

Collapsin-1 alkaline phosphatase fusion construct

Recombinant fusion proteins consisting of human placental alkaline phosphatase and the full coding sequence of collapsin-1 were produced in transiently transfected human 293T cells. Two different chimeras were made (Fig. 1A), one with alkaline phosphatase fused to the N-terminal end of collapsin-1 and another with the enzyme fused to the C-terminal end (Col-1–AP). To verify that collapsin-1 function is not compromised by the addition of alkaline phosphatase, we tested these fusion proteins for sensory growth cone collapsing activity in an in vitro assay. The specific collapsing activities of both the AP–Col-1 and Col-1–AP fusion proteins are as high or higher than that of collapsin-1 itself (Fig. 1B).

Visualization of collapsin-1 binding on cultured explants

Collapsin-1 is known to induce the collapse of DRG but not of retinal growth cones in vitro (Luo et al., 1993). A plausible inference is that DRG growth cones will bind collapsin-1, whereas retinal axons may not. Axons extending from E7 DRG explants were incubated with Col-1–AP for 1 hr at 37°C and fixed. The presence of alkaline phosphatase reaction product demonstrates the binding of collapsin-1 to DRG axons (Fig. 2B). Not only axons, but also collapsed growth cones, are intensely labeled with Col-1–AP (Fig. 2D). No binding is observed in the explants themselves or in migrating non-neuronal cells. We compared the collapsing activity and intensity of the AP signal at various concentrations of the Col-1–AP probe. If a CU is defined as the concentration of collapsin-1 required to collapse 50% of DRG growth cones, the binding of Col-1–AP to DRG axons is first detected at 5 CU, although staining intensity at this concentration is weak (data not shown). Fifty collapsing units, or ~100 ng/ml, give a strong AP signal. To test the specificity of the Col-1–AP signal, we tested whether unlabeled collapsin-1 could compete with Col-1–AP binding. No Col-1–AP binding is detected in DRG cultures simultaneously exposed to a 20-fold excess (~20 µg/ml) of unlabeled collapsin-1 (Fig. 2E). Even a 20-fold excess of unlabeled collapsin-1 reduces the intensity of the staining significantly (data not shown). The specificity of Col-1–AP binding was confirmed further by testing its ability to bind retinal growth cones. No detectable AP reaction product is observed on retinal ganglion cell axons or growth cones incubated in concentrations of Col-1–AP that give strong DRG labeling (Fig.

---

Kobayashi et al. / Sensory Axons Bind and Respond to Collapsin-1

Sensory Axons Bind and Respond to Collapsin-1

Visualization of collapsin-1 binding in sections

We next turned our attention to the distribution of collapsin-1 binding in the developing nervous system of the chick. Fresh-frozen sectioned embryos were lightly post-fixed in cold methanol and reacted with either Col-1–AP or AP–Col-1, and the alkaline phosphatase was reacted to form an insoluble product that accumulated where the probe was bound. Both probes revealed the same distribution of collapsin-1 binding on sections. Most figures in this paper were stained with AP–Col-1.

Spinal cord

As would be expected by their responsiveness to collapsin-1 and their ability to bind Col-1–AP in culture, sensory afferents in the spinal cord are heavily labeled with the probe. In sections of stage 26 embryos, the nascent dorsal sensory columns are well labeled (Fig. 3A). Decreased labeling is obtained when a 50-fold excess of unlabeled collapsin-1 competes with the AP–Col-1 probe, and no labeling is obtained when a 200-fold excess of unlabeled collapsin-1 is used (Fig. 3B). Not only the central projections but also the peripheral sensory projections bind AP–Col-1. The sensory nerve just distal to the DRG binds AP–Col-1 before it joins the ventral roots (Fig. 3A,C). Distal sensory projections may account for AP–Col-1 binding in the peripheral nerves; however, it is possible that binding to motor axons contributes as well. The growth cones of putative ventral spinal cord motor neurons have been shown to collapse in response to collapsin-1 (Shepherd et al., 1996), and the ventral roots of stage 21 embryos are clearly labeled with the probe (Fig. 3D). Much weaker labeling is sometimes apparent in the motor columns and ventral roots of older embryos (Fig. 3A). Collapsin-1 has been shown previously to induce the collapse of cultured sympathetic growth cones. It is therefore not surprising that dissociated sympathetic neurons and axons bind AP–Col-1 and that AP–Col-1 labels sympathetic ganglia in situ (Fig. 3D).

Centrally projecting sensory axons continue to bind AP–Col-1 as development proceeds. The binding of AP–Col-1 to sensory axons is compared to the distribution of collapsin-1 expressing cells at stage 30 in Figure 4, A and B. Collapsin-1 expression is concentrated in the ventral and medial portions of the gray matter, whereas the collapsin-1 sensitive sensory axons are con-
centrated in the dorsal and lateral portion of the white matter. This same complementariness is observed later in development. At stage 38, sensory afferents that bind AP–Col-I fill the dorsal horn (Fig. 4C) but do not enter the ventral gray matter where collapsin-1 expression is high (Fig. 4D). Interestingly, the most medial portion of the dorsal columns that contains a greater proportion of muscle afferents as compared with cutaneous afferents is less heavily labeled by AP–Col-I than are the lateral dorsal columns.

The binding of AP–Col-I to spinal sensory, motor, and sympathetic axons matches their known sensitivity to collapsin-1 *in vitro*. However, the real utility of the alkaline phosphatase fusion construct is the identification of new axon tracts likely to be sensitive to collapsin-1. We next examined the hindbrain to determine what neuronal types are likely to be collapsin-1 responsive.

**Trigeminal ganglion**

AP–Col-I binding is first detected in trigeminal axons at stage 18. The binding pattern in and around the trigeminal ganglion at stage 25 is shown in Figure 5A. Figure 6A is a schematic diagram of AP–Col-I binding reconstructed from serial sections. All three sensory nerves originating in the trigeminal ganglion, the ophthalmic, the maxillary, and the mandibular nerves, are intensely stained with AP–Col-I. The trigeminal root entering the brainstem as well as ascending and descending trigeminal axon tracts in the brainstem are strongly labeled. No AP–Col-I binding is detected in the trigeminal ganglion itself. Antigens raised against neurofilaments visualize fibers of passage through the trigeminal ganglion, axon tracts in the brainstem, and the peripheral nerve branches (Fig. 5B). Axons coursing through the ganglion that are not stained with AP–Col-I are likely to originate within the hindbrain from the motor and mesencephalic sensory nuclei of V. Figures 5C and 6B show the position of collapsin-1 expression within the hindbrain. Collapsin-1 is strongly expressed at the lateral border and more weakly expressed at the dorsal and medial margins of the descending trigeminal tract. Surprisingly, collapsin-1 is also expressed in and around the nerve V root where it enters the brainstem.

**Facial, acoustic, and vestibular ganglia**

AP–Col-I labeling in the vicinity of the fused VIIth (facial) and VIIIth (vestibulocochlear) ganglia at stage 25 is shown in Figure 5, E and F. A schematic diagram of AP–Col-I binding is shown in Figure 6A. Weak labeling is detected in the most distal portion of the proximal VIIth ganglion (Fig. 5E, arrow). This axonal staining can be followed into the nerve joining the proximal to the distal VIIth (geniculate) ganglion (Fig. 6A). The distal facial nerve also binds the AP–Col-I probe (Fig. 6A). There are no detectable AP–Col-I-labeled axons in either the acoustic or the vestibular portions of the VIIIth ganglion. In contrast, collapsin-1 expression is high in both portions of the VIIIth ganglion (Fig. 5G). Collapsin-1 is not expressed in the VIIth ganglion. In the hindbrain, AP–Col-I labeling is detected in a tract just lateral to the descending spinotrigeminal tract (Fig. 5E, arrowhead). As seen in Figure 6A, this tract courses just lateral to the entry point for VIIth and VIIIth ganglion axons. Labeling the central projections of VIIth and VIIIth sensory axons by applying Dil to the nerve root indicates that the AP–Col-I-labeled tract corresponds with ascending and descending sensory axons originating in the VIIth and/or VIIIth ganglion (Fig. 5J). Because AP–Col-I labeling in the periphery is only associated with nerve VII fibers, we attribute the lateral AP–Col-I positive projection in the brainstem to VIIth ganglion sensory fibers. Figures 5D and 6B show the position of collapsin-1 expression in the hindbrain near the VIIth and VIIIth nerve root. Collapsin-1 is expressed at the lateral border of the facial sensory tract and between the spinal trigeminal and the facial tracts.

**Glossopharyngeal and vagus nerves**

AP–Col-I labeling in the vicinity of the IXth (glossopharyngeal) and Xth (vagus) nerves at stage 25 is shown in Figure 5, H and I. A schematic diagram of AP–Col-I binding is shown in Figure 6A. Strong labeling is seen in the Xth nerve, but no labeling is detected in the IXth nerve or in the distal IXth (petrosal) ganglion. However, the proximal IXth ganglion (superior) is labeled with AP–Col-I (Fig. 6A).

**Olfactory bulb**

One dramatic example of the identification of a new axon tract likely to be sensitive to collapsin-1 is the labeling of axons originating in the olfactory sensory epithelium. The olfactory nerve is strongly stained with AP–Col-I at stages 23–25 (Fig. 7A). At this stage of development, the olfactory nerve spans the distance between the olfactory epithelium and the telencephalic vesicle. The olfactory bulb has not yet formed, and the sensory axons do not penetrate into the CNS. AP–Col-I binding is detected along the entire length of the nerve, from the olfactory epithelium to the end of the nerve at the surface of the telencephalon (Fig. 7C). Collapsin-1 is expressed in the olfactory epithelium (Fig. 7B) and in the most superficial layers of the telencephalon (Fig. 7D). Between stages 25 and 30, olfactory sensory axon endings appear to accumulate on the surface of the telencephalon (Fig. 7E), and collapsin-1 continues to be expressed superficially in the telencephalon (Fig. 7F). Olfactory sensory axons have invaded the nascent olfactory bulb by stage 38 and terminate in a superficial layer. They continue to bind AP–Col-I (Fig. 7G). At the same time, collapsin-1 is expressed in what is now an intermediate cell layer between the ventricular zone and the terminating sensory axons (Fig. 7H).

**Responsiveness of cranial sensory and olfactory growth cones to collapsin-1**

To test whether AP–Col-I binding predicts collapsin-1 responsiveness, we conducted collapse assays on selected axons found in this study to bind AP–Col-I *in situ*. Growth cones of axons growing from explanted stage 27–29 olfactory epithelia collapse in response to concentrations of recombinant collapsin-1 comparable with those that affect spinal sensory growth cones (Figs. 8A,B, 9). The same is true for the growth cones of explanted stage 29–30 trigeminal (Vth) ganglia (Figs. 8C,D, 9). Growth cones extending from the geniculate (distal VIIth) and the superior IXth ganglia are found to collapse in response to collapsin-1 (data not shown). Growth cones extending from stage 29–30 jugular (Xth) ganglia also collapse in response to collapsin-1 (Figs. 8G,H, 9). Axons from the VIIIth (vestibulocochlear) ganglion are not labeled with AP–Col-I on sections. In agreement with this observation, growth cones of axons originating in explanted stage 29–30 VIIIth vestibular ganglia do not collapse in response to collapsin-1 (Figs. 8E,F, 9). This is true even when they are exposed to a concentration of collapsin-1 10-fold greater than the concentration that induces 50% collapse of spinal sensory growth cones. All of these activity profiles are as predicted by the pattern of AP–Col-I binding observed in sections.
Figure 7. A comparison of AP–Col-1 labeling and collapsin-1 mRNA expression in the developing olfactory system. A, C, E, G, Sections probed with AP–Col-1. B, D, F, H, In situ hybridizations for collapsin-1 mRNA in matched but separate embryos. A, Axons (arrow) leaving the olfactory epithelium (OE) label with AP–Col-1 in stage 25 embryos. B, Collapsin-1 mRNA is expressed in the olfactory epithelium at this same stage. C, AP–Col-1 labels axons of the olfactory nerve (ON) where they make contact with the rostral tip of the telencephalic vesicle (TV) in a stage 25 embryo. D, Collapsin-1 mRNA is expressed in a superficial layer of the telencephalic vesicle. The olfactory nerve is marked with an arrow. Sections (Figure legend continues)
DISCUSSION

The objective of this study was to systematically identify axons in the developing chicken nervous system likely to be responsive to the signaling protein collapsin-1. We constructed alkaline phosphatase–collapsin-1 fusion proteins that should bind collapsin-1 receptors and thereby reveal their distribution in tissue sections.

The specificity and utility of these probes is demonstrated by several observations. AP–Col-1 and Col-1–AP are both at least as active as collapsin-1 in an *in vitro* collapse assay using DRG

---

were cut coronally, with dorsal right and medial down. *E*. Olfactory nerve axons (arrow) continue to accumulate on the surface of the telencephalon through stage 31. *F*. Collapsin-1 continues to be expressed in the most superficial layer of the telencephalon at stage 31. *G*. Olfactory nerve axons have entered the developing olfactory bulb (*OB*) and occupy the most superficial layer (arrow) by stage 38. *H*. Collapsin-1 mRNA is expressed at this time in more intermediate layers. Sections in *E–H* were cut 45° to the horizontal plane. Rostral is left, and medial is up. Scale bars: *B*, 100 μm; *A, C–H*, 200 μm.
growth cones, demonstrating their ability to bind the receptor with high affinity. Binding studies of AP–Col-1 on whole cultured sympathetic neurons indicate the presence of a high affinity binding site. This is the predicted result, because sympathetic growth cones collapse in response to concentrations of collapsin-1 of $\sim 30$ pM. We infer that the activation of a high affinity collapsin-1 receptor is likely to initiate sympathetic growth cone collapse.

The ability of AP-collapsin-1 constructs to bind a specific collapsin-1 receptor is supported further by their ability to specifically label appropriate axons in culture. Cultured collapsin-1 responsive DRG axons bind the Col-1–AP probe. Binding of the Col-1–AP probe can be detected with concentrations fivefold greater than those required to obtain 50% collapse, although concentrations 10-fold greater yield intense staining. Binding of the Col-1–AP probe is competed off with excess unlabeled probe, demonstrating that the probe and collapsin-1 compete for a limited number of specific sites on the cell surface. Cultured retinal axons do not bind detectable Col-1–AP at concentrations that give strong labeling of DRG axons. This result is consistent with the previous observation that retinal axons do not collapse in response to collapsin-1 (Luo et al., 1993). The specificity of the probe is demonstrated further by their specific patterns of binding in sectioned embryos. Only a small number of axon tracts are labeled in sections probed with AP–Col-1 or Col-1–AP. Tracts arising from neurons known to be collapsin-1 responsive are labeled, and those from neurons known to be unresponsive in collapsin-1 in vitro assays are not labeled. This labeling can be competed off with excess unlabeled collapsin-1, again demonstrating that the binding sites are specific and saturable.

The most important test of the utility of the AP-collapsin-1 probes is their ability to identify new collapsin-1 responsive axons. The binding of AP–Col-1 and Col-1–AP to primary olfactory sensory axons, as well as to axons extending from the trigeminal, facial, ciliary, and jugular ganglia, implies that these axons possess collapsin-1 receptors and are likely to be responsive to collapsin-1. Growth cones originating from these explanted neural tissues were subsequently all found to collapse in response to low concentrations of collapsin-1. In contrast, sensory growth cones extending from the VIIIth ganglion do not collapse in response to collapsin-1, as expected by their failure to bind AP–Col-1 in sections.

These findings demonstrate that chimeric alkaline phosphatase–collapsin-1 probes detect a specifically localized collapsin-1 binding component the presence of which on axons correlates with collapsin-1 responsiveness. It is likely that these
probes visualize a collapsin-1 receptor. Our estimation of affinity constants for the strength of binding between collapsin-1 and its receptor suggests the presence of high affinity receptor on sympathetic axons with a $K_a$ similar to the 30 pm of collapsin-1 that gives a half maximal collapse response, along with lower affinity sites of ~800 pm. Presumably, it is this high affinity binding site we see in sections, although we cannot exclude the possibility that we are visualizing a lower affinity binding site that colocalizes with a higher affinity collapsin-1 receptor.

The original rationale for this study was to correlate the distribution of collapsin-1 receptors with the expression pattern of collapsin-1. Such a comparison should suggest possible biological functions for collapsin-1 signaling in vivo. We now turn our attention to the relative distributions of collapsin-1 and putative collapsin-1 receptors in the spinal cord, brainstem, and olfactory system.

**Spinal cord**

Collapsin-1 may play an important role in the organization of DRG sensory afferents in the spinal cord. It is expressed at high levels in the ventral cord and at lower levels in the dorsal gray matter of the cord at stage 23 when sensory afferents first enter the dorsal roots (Shepherd et al., 1996). Sensory axons extend within the developing dorsal columns for the next 2 d, but their afferent branches do not invade the dorsal gray matter until stage 28–29 (Davis et al., 1989). Their entry correlates with a concomitant loss of collapsin-1 expression in the nascent dorsal horn (Shepherd et al., 1997). All growth cones extending in vitro from E7 DRG ganglia appear to collapse in response to collapsin-1 (Luo et al., 1993; Püschel et al., 1996; Sharma et al., 1996; Shepherd et al., 1997). It is therefore possible that the loss of collapsin-1 expressing cells in the dorsal gray matter around stage 29 permits collapsin-1 sensitive sensory afferents to enter the spinal gray matter. Consistent with this hypothesis is the presence of strong AP–Col-1 binding on axons within the dorsal columns throughout the time course of these events.

DRG afferents can be classified by their ultimate destinations in the spinal cord. Most afferents terminate in various laminae within the dorsal horn and never extend into the ventral cord. A minority of afferents, including the group Ia stretch receptors, ultimately extend into and synapse within the ventral cord (Brown, 1981; Willis and Coggshall, 1991). Collapsin-1 expression is gradually confined to the ventral cord between stages 30 and 36. Dorsally terminating afferents remain collapsin-1 sensitive and are confined to the dorsal cord by ventrally expressed collapsin-1, whereas ventrally terminating afferents become collapsin-1 insensitive and are thereby able to invade the ventral cord (Messersmith et al., 1995; Behar et al., 1996; Püschel et al., 1996; Shepherd et al., 1997). In agreement with this, AP–Col-1 only labels the dorsal gray matter. Interestingly, by stage 38 the most medial portion of the dorsal white matter binds significantly less AP–Col-1 than does the more lateral dorsal white matter (Fig. 4C). This medial portion of the white matter is enriched in TrkC-positive, ventrally invading afferents (Oakley et al., 1997). TrkA-positive dorsally terminating afferents are predominant in the more lateral white matter where strong AP–Col-1 binding is evident. These results suggest that ventrally invading afferents become collapsin-1 insensitive because they lose the collapsin-1 receptor. The cell- and time-specific downregulation of collapsin-1 receptor expression may control which sensory afferents invade ventrally and at what developmental time they begin their invasion.

**Hindbrain**

Sensory axons extending from ganglia contributing to the Vth (trigeminal), VIIth (facial), and Xth (vagus) cranial nerves bind AP–Col-1 and collapse in response to collapsin-1. This collapsin-1 responsiveness could play a role in the guidance of these axons in the periphery, as proposed previously for the peripheral axons of DRG sensory axons (Wright et al., 1995). The finding that collapsin-1 responsive sensory axons abut collapsin-1-expressing cells in the brainstem suggests that collapsin-1 may help to define the medial and lateral limits of these central sensory tracts. Collapsin-1 expression between the central spinal trigeminal and VIIth sensory tracts may help keep them separate.

**Fused VIIth and VIIIth ganglia**

The VIIth and VIIIth nerves share the same entry point into the hindbrain. In the chick, there are two facial sensory ganglia, a distal (geniculate) ganglion and a more proximal ganglion that is fused with the VIIIth (vestibular) ganglion (Yamamoto and Schwarting, 1991). Axons extending from these ganglia enter the hindbrain through the fused VII and VIII nerve root. Centrally projecting facial sensory axons must therefore navigate through a choice point where they choose to enter the VII and VIII root and not the VIIIth ganglion. Collapsin-1 is expressed in both the vestibular and acoustic parts of the VIIIth ganglion. AP–Col-1 binds to VIIth nerve axons, and growth cones extending from explanted VIIth ganglia respond to collapsin-1. This complementary pattern of collapsin-1 expression and collapsin-1 receptor distribution suggests that collapsin-1 in the VIIIth ganglion denies entry to collapsin-1 responsive VIIth nerve axons growing toward the brainstem.

**Olfactory system**

Just as spinal sensory afferents observe a waiting period before they enter the gray matter of the spinal cord, axons in the olfactory nerve wait on the surface of the telencephalon before entering the developing olfactory bulb. The time course of olfactory nerve innervation of the bulb has been extensively studied in rodents (Doucette, 1989; Marin-Padilla and Amieva, 1989; Santacana et al., 1992). Olfactory sensory epithelial axons grow through the mesenchyme between the epithelium and the telencephalon, turn anteriorly once they reach the telencephalon, and stop where the olfactory bulb will later differentiate. Although a small number of pioneer olfactory axons transiently penetrate into the telencephalon, the vast majority of olfactory axons accumulate for days outside the CNS without entering (Valverde et al., 1992; Gong and Shipley, 1995). These fibers only enter the CNS as the telencephalic vesicle begins to evaginate when the olfactory bulb starts to form. Olfactory nerve axons ultimately terminate in glomeruli located within a superficial layer of the bulb.

Although much less information is available about these events in the developing chick, our observations are consistent with this general scheme (Fig. 10). Olfactory nerve axons have arrived at the telencephalic surface by stage 25 (Fig. 10, St. 25) but have not invaded the CNS even by stage 31 (Fig. 10, St. 31). Interestingly, throughout this time period, collapsin-1 is expressed within the most superficial layers of the telencephalic vesicle (for similar observations in the rat, see Giger et al., 1996). Our demonstration that AP–Col-1 binds to olfactory sensory axons and that collapsin-1 collapses olfactory growth cones in vitro suggests that collapsin-1 prevents olfactory axon entrance into the telencephalon during this period. By stage 38, olfactory axons have invaded...
the nascent olfactory bulb and now occupy its outermost layer (Fig. 10, St. 38). At this stage of development, collapsin-1 is expressed in an intermediate layer just beneath the olfactory axon terminations. We therefore predict that sensory axons are confined to superficial layers of the olfactory bulb by the expression of collapsin-1 in intermediate layers.

Both in the dorsal horn of the spinal cord and in the olfactory bulb, collapsin-1 receptive sensory axons are excluded for several days from immediately adjacent areas that express collapsin-1. In both cases, the final pattern of sensory axon termination is complementary to the distribution of collapsin-1 expression. Thus, both the timing of target penetration and the final spatial localization of terminations may be controlled by the timing and localization of collapsin-1 expression.

REFERENCES


